Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production
June 03, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Labs (OTCQB: KBLB) is now in production with its BAM-1 spider silk hybrids, following the resounding successes of its spring production trials
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Celcuity Announces Pricing of Underwritten Common Stock Offering
May 30, 2024 07:36 ET
|
Celcuity Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
May 29, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024 08:00 ET
|
23andMe, Inc.
The LRRK2 variant is strongly associated with symptoms of Parkinson’s disease (PD) that are different from non-variant carriers with the diseaseThe study revealed novel findings of genetic “hotspots”...
Tevogen Bio Reports First Quarter 2024 Financial Results
May 29, 2024 08:00 ET
|
Tevogen Bio Inc
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024 16:30 ET
|
Cellectis Inc.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference...
Evaxion Announces Business Update and First Quarter 2024 Financial Results
May 28, 2024 08:21 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...